IU Health buying docs in hospital ventures
Indiana University Health is now quietly unwinding the physician ownership of its hospitals in Carmel and Avon—which sparked loud controversy when they opened in 2004 and 2005.
Health Care & Life Sciences
Articles
Health insurers lose push to ease rate review
U.S. insurers led by WellPoint Inc. and UnitedHealth Group Inc. failed to get federal regulators to change a rule in the 2010 health-care overhaul that triggers a review of any premium increases exceeding 10 percent.
Franciscan Alliance takes control of VNS home health agency
Visiting Nurse Service Inc., a 200-employee agency based in Indianapolis, will operate under the umbrella of Franciscan St. Francis Health, the organizations announced Thursday.
Riley Hospital CEO resigns
Dan Fink, who joined Riley Hospital for Children nearly six years ago, will depart Friday. Marilyn Cox will serve as interim president and CEO while Riley conducts a national search for a new leader.
Growth in drug spending to slow as generics rise
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
LEADING QUESTIONS: Wishard’s top doc stays true to roots
How can practicing medicine prepare you for a CEO post? And why is it smart to continue seeing patients once you get the top job? Dr. Lisa Harris will see you now with answers.
WellPoint approves annual ‘say on pay’ measure
Shareholders of WellPoint Inc. approved on Tuesday the hefty pay packages of the company’s executives and voted for the right to weigh in annually on future executive compensation.
Prescription drug abuse growing problem in Indiana
Prescription drugs are playing an increasing role in the drug-related crimes that are filling up Indiana's prisons, prison officials and prosecutors said.
VCs: Health benefits will be defined contribution
Increasing government involvement in the health insurance market will have the counter-intuitive effect of making the industry more consumer-driven, concludes a new report from a health care venture-capital firm.
Zimmer faces new threat to dominance
Warsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement implants to hospitals. But now it faces a challenge from Johnson & Johnson.
Financial strength ratings of OneAmerica subsidiaries climb even higher
Indianapolis-based firm avoided investment losses suffered by peers during last recession.
Eli Lilly’s slumbering stock finally shows signs of life
Is it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted thousands of millionaires?
Northwest-side medical building facing foreclosure
The operator of the building at 8424 Naab Road near St. Vincent Hospital is accused of owing an Illinois investment firm $4 million.
Health care providers opening to technology
Some health care system are finally allowing online scheduling.
MANTOOTH: Companies bogged down by employees’ poor health
The problem is, too many people make unhealthy choices and the consequences of these choices become everyone’s problem.
Reform could create more ’boutique’ doctors
Health reform could accelerate trend toward two tiers of care, with concierge services like Dr. Matt Priddy offers at the top and long waits and minimal attention at the bottom.
Lilly drug to detect Alzheimer’s criticized by consumer group
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
IU Health LaPorte Hospital eliminates 112 jobs
Hospital President and chief executive officer Thor Thordarson said in a news release the jobs cuts were necessary because of the higher costs facing health care providers.
Two wins to bring Lilly modest sales
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
Endocyte’s potential enthralls investors
Shares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common wisdom is it won’t see sales from its first cancer drug until 2014.